The Food and Drug Administration (FDA) has asked Congress to help develop a “cross-agency strategy” for creating a “new regulatory pathway” for CBD. In short, FDA states a “new.
Cannabis industry stakeholders waiting for the US Food and Drug Administration (FDA) to forge a regulatory path forward for cannabidiol (CBD) in consumer products such as conventional foods.
On January 26, the U.S. Food and Drug Administration (FDA or the Agency) announced that it is prepared to work with Congress to develop a new regulatory pathway for cannabidiol (CBD).